Single-Dose Azithromycin for Respiratory Tract Infections

Annals of Pharmacotherapy

Volumn 38, Issue 3, 2004, Pages 433-439

  Law, Constance ^a,b   Amsden, Guy W ^b,c  

^a Dept of Adult and Pediat Medicine   (United States)

^b BASSETT RESEARCH INSTITUTE   (United States)

^c Section of Clinical Pharmacology   (United States)

Author keywords

Azalide; Azithromycin; Community acquired pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN; CLARITHROMYCIN; MACROLIDE; PENICILLIN G; TETRACYCLINE;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; MEDICAL LITERATURE; MEDLINE; OTITIS MEDIA; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SINGLE DRUG DOSE; TIME; TONSILLITIS; URTICARIA; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; OTITIS MEDIA; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY TRACT INFECTIONS; SAFETY;

EID: 1242271407     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D001     Document Type: Review

References (35)

1. Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992;26:1253-61.
2. Kardas P, Ratajczyk-Pakalska E. Patient adherence in respiratory tract infections: ceftibuten versus other antibiotics. Polski Merkuriusz Lekarski 2001;10:445-9.
3. Steele RW, Thomas MP, Begue RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J 2001;20:1-5.
4. Reyes H, Guiscafre H, Munoz O, Perez-Cuevas R, Martinez H, Gutierrez G. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 1997;50:1297-304.
5. Branthwaite A, Pechere JC. Pan-European survey of patients' attitudes to antibiotics and antibiotic use. J Int Med Res 1996;24:229-38.
6. Craig WA. Postantibiotic effects and the dosing of macrolides, azalides and streptogramins. In: Zinner SH, Young LS, Acar JF, Neu HC, eds. Expanding indications for the new macrolides, azalides, and streptogramins. New York: Marcel Dekker, 1997:27-38.
7. Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother 1999;43:163-5.
8. Wildfeuer A, Laufen H, Leitold M, Zimmermann T. Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. J Antimicrob Chemother 1993;31 (suppl E):51-6.
9. Amsden GW, Gray CL. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother 2001;47:61-6.
10. Package labeling. Zithromax (azithromycin). New York: Pfizer Labs, May 2002.
11. Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother 1995;39:1875-7.
12. Tajima T, Kobayashi M, Abe T, Fujii R. [Pharmacokinetic, bacteriological and clinical studies on azithromycin in children]. Japanese. Jpn J Antibiot 1997;50:200-5.
13. Craig WA. Does the dose matter? Clin Infect Dis 2001;33(suppl 3):S233-7.
14. Zhanel GG, Noreddin A, Bewick BB, Laing N, Roberts DM, Nichol K, et al. In vitro pharmacodynamic modelling of clarithromycin and azithromycin simulating serum and epithelial lining fluid concentrations versus mefA and ermB macrolide-resistant Streptococcus pneumoniae (abstract 5.02). Presented at: Sixth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Bologna, Italy, January 23-25, 2002.
15. Amsden GW. Pneumococcal macrolide resistance-myth or reality? J Antimicrob Chemother 1999;44:1-6.
16. Mandell GL, Coleman EJ. Activities of antimicrobial agents against intracellular pneumococci. Antimicrob Agents Chemother 2000;44:2561-3.
17. Klein JO. Current issues in upper respiratory tract infections in infants and children: rationale for antibacterial therapy. Pediatr Infect Dis J 1994;13(1 suppl 1):S5-9.
18. Kozyrskyj AL, Hildes-Ripstein E, Longstaffe SEA, Wincott JL, Sitar DS, Klassen TP, et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA 1998;279:1736-42.
19. Briefing document for Zithromax accelerated dosing - treatment of acute otitis media. Protocol R-0581. Food and Drug Administration. www. fda.gov/ohrms/dockets/ac/01/briefing/3802b1_01_Pfizer.pdf (accessed 2002 Nov 16).
20. Briefing document for Zithromax accelerated dosing - treatment of acute otitis media. Protocol AZM-NY-95-001. Food and Drug Administration. www.fda.gov/ohrms/dockets/ac/01/briefing/3802b1_01_Pfizer.pdf (accessed 2002 Nov 16).
21. Dunne MW, Khurana C, Mohs AA, Rodriguez A, Arrieta A, McLinn S, et al. Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis. Antimicrob Agents Chemother 2003;47:2663-5.
22. Dowell SF, Butler JC, Giebink GS, Jacobs MR, Jernigan D, Musher DM, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
23. Dagan R, Johnson CE, McLinn S, Abughali N, Feris J, Leibovitz E, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000;19:95-104.
24. Briefing document for Zithromax accelerated dosing-treatment of acute otitis media. Pediatric OM briefing document. Food and Drug Administration. www.fda.gov/ohrms/dockets/ac/01/briefing/3802b1_01_Pfizer.pdf (accessed 2002 Nov 16).
25. Foulds G, Luke DR, Teng R, Willavize SA, Friedman H, Curatolo WJ. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996;37(suppl C):37-44.
26. Amsden GW, Duran JM, Amankwa K, Victory JM, Willis S. Tolerance of high-dose oral azithromycin (AZ) regimens (abstract 4.12). Presented at: Sixth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Bologna, Italy, January 23-25, 2002.
27. Pinner RW, Teutsch SM, Simonsen L. Trends in infectious diseases mortality in the United States. JAMA 1996;275:189-93.
28. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.
29. Bartlett JG, Breiman RF, Mandell LA, File TM. Guidelines from the Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
30. Niederman MS, Mandell LA, Anzuteto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001;163:1730-54.
31. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as a 3-day therapy in respiratory tract infections. Drugs 1996;51:483-505.
32. Schönwald S, Kuzman I, Oreskovic K, Burek V, Škerk V, Car V, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study. Infection 1999;27:198-202.
33. Schönwald S, Kuzman I, Škerk V, Car V, Zrinšć ak J, Puljiz I, et al. Comparative clinical study of the tolerability and efficacy of two dosage regimens of azithromycin and clarithromycin in the treatment of community-acquired pneumonia in adults (progress report) (abstract 4.34). Presented at: Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, January 26-28, 2000.
34. Gwaltney JM Jr, Bisno AL. Pharyngitis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000:656-62.
35. Karpov OI, Zaytsev AA, Karpischenko SA. Single oral 1.5 g azithromycin dose in the treatment of uncomplicated tonsillitis in adults-pilot study (abstract 4.13). Presented at: Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, January 26-28. 2000.